Simtriyo (Centanafadine) for ADHD: Heard about it on TikTok? Here’s What We Actually Know

Aug 3

Recently, I received a patient question about an ADHD medication that was just approved on July 24th, 2026 and creating a buzz on TikTok.

Let’s talk about it!

The new ADHD med is called Simtriyo (the generic name is centanafadine).

Note: The way you’ll actually see it is in all caps (SIMTRIYO). But to avoid sounding like I’m screaming it everytime you read it, you will see it as the tempered: Simtriyo. Or the generic name, centanafidine. SORRY, Otsuka.

The brand name comes from the fact that at the same time ("sim"), it affects three neurotransmitters (the "triyo"). Otsuka hasn’t confirmed this is actually the naming logic anywhere I could find. But, we see what you did there!

In this very detailed guide, I’ll walk you through what it is, clarify points of confusion, and cover some logistical details.

Specifically, new approvals are exciting - but the reality of how accessible it is, and why many people may never end up on this medicine (like it’s cousin ADHD nonstimulant Qelbree) has more to do with pricing, insurance approvals, and real clinical practice logistics.

To be upfront: I haven’t prescribed this yet. Nobody has (outside of research). It’s FDA approved now, but it’s not sitting on a pharmacy shelf until later in 2026, and I’ll get into why.

What Simtriyo actually is

Simtriyo is the brand name for centanafadine, an extended-release capsule taken once a day, approved for ADHD in adults and in kids 6 and up who weigh at least 20 kg (44 lbs).

It comes in three doses: 140 mg, 210 mg, and 280 mg.

For adults, the maximum recommended dose is 280mg.

Children 6-12 get weight-based dosing. Those 13-17 are recommended to get the 280 mg dose right away because the lower dose didn’t separate from placebo in that age group, so it’s not an approved option for teens even though it exists as a capsule strength. However, in my clinical opinion start lower if you want to ensure tolerability first.

You can swallow it whole, or if that’s not happening, open the capsule and sprinkle it on a spoonful of applesauce or yogurt, or in orange juice, and drink it right away.

Take it in the morning, with or without food.

Notes for the nerds:

Quick flag on that 400 mg number floating around some sources (including, at first, something I pulled myself from the research): it’s not the approved dose. The pivotal adult trials used what the FDA label calls "another formulation of centanafadine": an older, twice-daily tablet that went up to 400 mg/day and never got approved on its own. The label bridges that old data onto the actual capsule with this line: "There are no expected differences in effectiveness of the low and high doses of the other centanafadine formulation compared to SIMTRIYO 210 mg and 280 mg once daily, respectively." So 280 mg once daily is the real ceiling for adults, not 400.

One more unit thing worth knowing, also straight from the label: if you go looking at the original adolescent trial paper, you’ll see the dose reported as 328.8 mg instead of 280 mg. Same dose, just measured differently: 328.8 mg is the hydrochloride salt weight, 280 mg is the free base weight the label uses, and the two convert cleanly (280 × 1.174 ≈ 328.8). Not a different dose, not a mistake, just two units for one number. Phew.

Is it a stimulant or not?

It’s an interesting drug from a nerdy psychopharmocology perspective!

Many resources are calling it a non-stimulant.

It will be considered a controlled substance, a stimulant – and I’ll mention why below.

Short version: the abuse-potential studies are the actual reason it’s getting scheduled. The dopamine-transporter activity is my best explanation for why those studies came out the way they did – it’s maybe not a second, independent reason regulators are weighing alongside the first.

The official FDA label calls it "a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant."

That’s why despite July’s approval, and despite not having direct effect on dopamine release, it’s still awaiting the DEA’s controlled substance classification before it’s available in pharmacies. And that’s why you have to wait until at least late 2026.

It carries a boxed warning about abuse potential, the same class of warning other stimulants carry, like Adderall and Vyvanse.

Amphetamines (like Adderall and Vyvanse) directly force dopamine out of the neuron by essentially breaking into the storage vesicles and running the transporter in reverse (a releaser, in the jargon). I call it like squeezing a ketchup bottle (and you can’t squeeze from an empty bottle – which is why sleep and nutrition are also important to make the most of your meds!).

Centanafadine doesn’t do that (direct release). It’s a re-uptake inhibitor. It blocks reuptake of norepinephrine, dopamine, and serotonin at the transporter, the same basic move that methylphenidates and atomoxetine do.

What is a re-uptake inhibitor?

Basically, if the cell is the home and the inter-cellular space is the street, once these molecules have been squeezed out of their cell home, these medicines keep the door closed for longer – which keeps more molecules in the "streets" to be seen and interacted with, before they come back. This is what we mean by there being "more" in the brain – there is "more" of them to stimulate receptors. They’re out “ringing doorbells” (pressing receptors) on other cells.

Mechanistically, it’s closer in family to the stimulant class of methylphenidates than to the stimulant amphetamines. Methylphenidates are technically reuptake inhibitors too (of dopamine and norepinephrine), but the abusability studies and their strong dopamine-transporter activity is exactly why they’re also scheduled as stimulants. Centanafadine is also similar to the nonstimulant atomoxetine (Strattera) because it too is a re-uptake inhibitor (of norepinephrine, and super indirectly of dopamine).

I think that’s a more honest way to explain this to patients than either "it’s basically Adderall" or "it’s basically Strattera," because it’s neither.

So why is centanafadine going to be classified as a stimulant? Really it’s one reason, with a likely explanation underneath it. The reason itself, the thing regulators are actually acting on: how abusable it felt to real people in testing. The explanation for why it felt that way: its direct effect on the dopamine transporter, which atomoxetine simply doesn’t have.

From the actual human abuse-potential studies Otsuka ran: at higher doses, people with a history of recreational stimulant use rated centanafadine’s "drug liking" about as high as amphetamine 40 mg, and reported elevated or euphoric mood at rates comparable to amphetamine and lisdexamfetamine. Atomoxetine has never shown that pattern in abuse-liability testing.

So it’s not really the norepinephrine-blocking part of the mechanism that earned centanafadine the stimulant label – atomoxetine blocks NET too, and it’s not scheduled. It’s the dopamine-transporter engagement atomoxetine doesn’t have, showing up exactly the way you’d predict once real people took it recreationally.

Additionally, it is a direct re-uptake inhibitor of the DAT dopamine transporter. Dopamine has a strong role in a substance’s addictiveness. (To be fair to the label here: it states the reuptake-transporter mechanism and the "CNS stimulant" designation in the same sentence, and reports the abuse-liability study results separately – it doesn’t explicitly draw this DAT-to-drug-liking line itself. That connection is my read on standard stimulant pharmacology, not something the label or Otsuka says outright.)

(I can explain how atomoxetine engages DAT but indirectly later, for the fellow nerds!)

One genuinely reassuring thing buried in the label: in the phase 3 trials, when adults stopped centanafadine abruptly, they had withdrawal symptoms indistinguishable from placebo. The label’s own conclusion is that despite being classified as a stimulant, it doesn’t appear to cause physical dependence. It’s supposed to be easy to stop – which would be a huge plus! I hope that really does pan out that way.

So does it work right away?

Somewhere in between. Not as fast as a stimulant, but noticeably faster than atomoxetine’s slow build.

– Stimulants: full effect within hours of the first dose.

– Centanafadine: measurable benefit by week 1, continuing to improve through the typical 6-week trial endpoint.

– Atomoxetine (Strattera): real but small effect by week 1, still climbing at 6 months in adults.

– Viloxazine (Qelbree): similar shape – improvement by week 1 (100 mg) or week 2 (200-400 mg), plateauing around 4-6 weeks.

– Guanfacine XR: titrated up over roughly a month; most trials assess full effect around 4-8 weeks.

On centanafadine specifically: it separates from placebo by week 1 – the earliest timepoint measured in every trial – and that holds up consistently. The adult phase 2b study found an effect size of 0.66 by week 3, with "significant efficacy demonstrated as early as week 1." The adolescent trial showed the high dose (328.8 mg) separating at week 1 and holding through week 6 (Cohen’s d −0.40). The children’s trial showed the same pattern (−16.3 vs −10.8 at week 6, separation at week 1). The adult phase 3 trials that led to approval showed end-of-study effect sizes of 0.24–0.40, depending on dose and study. One honest caveat: none of these trials measured same-day or next-day response, so whether there’s any benefit before the one-week mark is genuinely unknown, not just unreported.

On atomoxetine – in adults, a pooled analysis of two 26-week trials found the effect size climbing the whole time: 0.28 at week 1 (already statistically significant), 0.45 at week 4, and still growing to 0.52 at week 26 – six months in, and it hadn’t leveled off. In children, a separate pooled analysis (338 kids, open-label, followed for up to a year) found the median time to a 25% symptom improvement was 3.7 weeks, and the odds of a robust response (a 40%+ drop in ADHD-RS scores) kept climbing well past 6-9 weeks, up to 96% by 52 weeks. Different studies, different ages, same basic story: atomoxetine keeps working better the longer you’re on it, for longer than most people expect.

How it actually works

Centanafadine blocks reuptake at all three monoamine transporters – norepinephrine (NET), dopamine (DAT), and serotonin (SERT).

As we mentioned before – without directly releasing it, the "you can’t come back in" block keeps more of each neurotransmitter "out on the streets", so that they can continue being detected by other cells (pressing doorbells, in the metaphor).

But it’s not balanced across the three.

Otsuka’s own patent filing describes it as "unbalanced," with the strongest affinity for NET (norepinephrine), about a sixth as much for DAT (dopamine), and about a fourteenth as much for SERT (serotonin – SERT is the transporter’s name, not a reference to the drug sertraline, easy mix-up given how similar they look).

A small phase 1 PET imaging study (10 healthy men, so take the precision here with a grain of salt) found NET (norepinephrine transporter) occupancy in the 64-82% range at therapeutic exposure, with DAT (dopamine transporter) around 47% and SERT (serotonin transporter) around 44%. I mention the numbers mostly to make a point: the dopamine and serotonin occupancy are both well under half-maximal blockade, which tracks with why the drug is described as having a "novel" but modest effect, not a dramatic one.

So despite "triple reuptake inhibitor" sounding like equal parts of everything, this is really a norepinephrine drug first (a bit more like atomoxetine/Strattera) with meaningfully smaller dopamine and serotonin effects riding along.

It’s rare for a traditional ADHD medication to affect serotonin at all.

The only other one that does is the nonstimulant viloxazine (Qelbree), through a different door: viloxazine is a 5-HT2C receptor partial agonist (plus 5-HT2B and 5-HT7 receptor antagonist) – a receptor, not a transporter – so it’s not doing the same thing centanafadine does at all.

What’s a receptor agonist (or antagonist)?

If the transporter is the door to the neurotransmitter's home:

Reuptake inhibitors work by keeping that door closed for longer. That means the neurotransmitters stay out walking around outside, being detected by other cells as there being “more” around. While these extra molecules are out and about, they can ring more doorbells.

Receptor agonists work like walking up to the cell home and ringing the doorbell themselves (“Hi, I’m not serotonin, but I’m a rep”) – that’s whether or not there's more of the real neurotransmitter around to do it. A receptor agonist is like the molecule’s personal representative.

A partial agonist presses the doorbell, just not as hard. Maybe let’s say, it knocks softly.

An antagonist stands in front of the doorbell like a body guard, so that nobody can press it, the real neurotransmitter included.

SSRIs and centanafadine have serotonin re-uptake inhibitor properties: both work by blocking SERT (the serotonin transporter), so more serotonin sits around in the synapse, ringing doorbells.

Buspirone (not an ADHD medicine) works by directly “ringing the doorbell” of the 5-HT1A receptor.

Viloxazine (nonstiulant ADHD medicine) works by “ringing the doorbell” of 5-HT2C (and turning off 5-HT2B/5-HT7).

Same neurotransmitter, three different ways of affecting it.

That’s part of the uniqueness. While another ADHD nonstimulant (Quelbree aka viloxazine) affects serotonin, only centanafidine affects serotonin in the way that SSRIs also do!

Centanafadine’s SERT occupancy is modest – around 44% at therapeutic doses, well under the roughly 80% you’d see with a standard-dose SSRI. Loosely, that’s probably closer to what a low dose of an SSRI would do than a full therapeutic one. Theoretically that could carry some mild anxiolytic or mood effect alongside the ADHD benefit – but I don’t want to turn a 44% occupancy number into a promise before we have the outcome data to back it up.

Here’s what we actually have, though, and it’s more than I expected: Otsuka ran a real phase 3b trial specifically in adults with ADHD and comorbid anxiety (generalized or social), enriched for people who’d already failed at least two ADHD medications and two anxiety medications – a genuinely hard-to-treat group. Centanafadine beat placebo on ADHD symptoms as usual, and it also significantly improved anxiety itself, measured on the Hamilton Anxiety Rating Scale (−12.5 vs −10.6, p=0.02) at 8 weeks. That’s a dedicated anxiety trial, not an inference from mechanism.

Now here’s the wrinkle that undercuts a clean "it’s the serotonin" story: atomoxetine has zero serotonin activity – it’s a pure norepinephrine reuptake inhibitor, nothing else – and it also has real trial data showing anxiety improvement, in both adults (a dedicated social anxiety disorder trial) and kids. So an ADHD medication improving comorbid anxiety clearly doesn’t require touching serotonin at all. Whether that’s norepinephrine doing its own work on anxiety circuits, or just ADHD symptoms themselves driving a chunk of someone’s anxiety and easing up once those symptoms improve, or both – genuinely unclear, and I haven’t found anything that cleanly separates those explanations. Viloxazine’s own researchers say almost exactly this about their drug’s serotonin receptor activity: whether it actually contributes to the clinical response "is unknown and warrants further investigation." I’d hold centanafadine’s anxiety result to that same standard until someone runs a real head-to-head.

Does it work?

Yes, but modestly, and short-term data is what we mostly have.

In the two pivotal adult trials, the placebo-subtracted improvement in ADHD symptom scores ranged from about 2.7 to 4.4 points, depending on study and dose. In teens, it was 4.4 points; in kids 6-12, 5.6 points. These are statistically real differences, not statistical noise, but they’re smaller than what you typically see with stimulants, and the placebo-controlled evidence only goes out to 6 weeks (more on the longer-term data next) – though for kids and teens specifically, I haven’t found anything published past that mark yet.

In short: just like with atomoxetine/Strattera, it’s great for some, but not the clear effect you might get from stimulants. For some people, that subtlety is the better option.

There’s a 52-week open-label extension in adults that suggests the benefit holds up longer-term, but open-label means everyone knew what they were taking, so it’s a weaker kind of evidence than the placebo-controlled trials. (For example, could people have rated doing better on it since they knew and were excited to be taking a "new, shiny" drug or at the prospect of a better side effect profile, etc).

Indirect comparisons (matching-adjusted, not head-to-head – a distinction that matters more than it sounds like it should) suggest centanafadine has a meaningfully better side-effect profile than lisdexamfetamine, atomoxetine, and viloxazine, but is less effective than lisdexamfetamine and roughly comparable to atomoxetine and viloxazine.

So generally: less effective than a stimulant, but easier to tolerate.

The two boxed warnings

Neither is unique to this drug, but you should know about them.

Suicidal ideation and behavior in kids 6 and up. In the 6-12 year old trial, 2 of 304 kids on centanafadine had a suicide attempt versus 0 of 153 on placebo. Small numbers, real signal. Close monitoring in the first few months matters here the way it does with any new psychiatric medication in a kid, maybe more so given this finding specifically.

Abuse, misuse, and addiction. Standard CNS stimulant class warning, not actually moreso in this drug vs any other in the class. Assess risk before starting, keep it locked up, don’t give it to anyone else, the usual counseling we already give for ADHD medicines and stimulants.

Other things in the label worth knowing about: avoid it in serious structural heart disease, watch blood pressure and heart rate, it can trigger new psychotic or manic symptoms even without a prior history (about 0.1% in pooled stimulant trials, so rare but real), it’s been associated with growth suppression in kids on long-term treatment, and there’s a Raynaud’s/peripheral vasculopathy warning shared across the stimulant class. The 210 mg capsule specifically contains FD&C Yellow No. 5 (tartrazine), which matters for anyone with aspirin sensitivity.

Drug interactions, and one correction

I want to flag something I got wrong in my own head initially, because I think it’s a useful example of how easy it is to reason your way to a plausible-sounding wrong answer with a brand-new drug.

Some sources suggested that CYP2D6 liver enzyme inhibitors like fluoxetine and paroxetine would raise centanafadine levels, the way they do with atomoxetine. That turns out to be the wrong mechanism entirely.

Per the official FDA drug label: Centanafadine is metabolized primarily by monoamine oxidase A, not CYP enzymes, and the label specifically tested quinidine (a CYP2D6 inhibitor) and found no meaningful change in centanafadine levels.

So the fluoxetine/paroxetine concern doesn’t apply to it. Which is great, since it’s been a big barrier for those interested in atomoxetine/Strattera (which is increased by fluoxetine/Prozac).

Something important to note, since caffeine is so common: it doubles your caffeine exposure! So you may need to cut down or stop.

What does matter:

– MAOIs are an absolute contraindication – current use or within 14 days of stopping one. Risk of hypertensive crisis and serotonin syndrome.

– Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans, tramadol, fentanyl, meperidine, methadone, tryptophan, St. John’s Wort) can raise serotonin syndrome risk when combined. Not contraindicated, just something to monitor for and be careful with.

– Other CNS stimulants add to blood pressure and heart rate effects.

– CYP1A2 substrates – centanafadine is a moderate CYP1A2 inhibitor and roughly doubles caffeine exposure in a PK study. Worth knowing if you drink even some coffee (or other caffeinated beverages!), and relevant for other CYP1A2 substrates like some antipsychotics (clozapine and olanzapine are the classic examples clinicians watch for).

One interesting negative finding on centanafadine’s own levels: smoking, which usually induces CYP1A2 and would be expected to lower levels of drugs cleared that way, didn’t meaningfully change centanafadine’s own levels in the label’s interaction studies – makes sense, since centanafadine is mainly cleared by MAO-A rather than CYP1A2, so CYP1A2 induction doesn’t have much to act on.

But here’s the nuance that trips people up: it’s the combustion, not the nicotine, that does the inducing. Meaning, cigarette smoke or marijuana smoke does this (and vaping nicotine or THC does not). Cigarette smoke’s CYP1A2 induction comes from polycyclic aromatic hydrocarbons (PAHs) generated by burning tobacco, not from nicotine itself: which is why nicotine patches, gum, and vaping (no combustion) don’t induce CYP1A2 the way smoking does. Cannabis smoke contains those same PAHs and induces CYP1A2 the same way, by the same combustion mechanism, regardless of THC or CBD content. So it’s a combustion question, not specifically a nicotine or cannabis one.

Where this actually matters for centanafadine: not for centanafadine’s own levels (unaffected, per above), but for any other CYP1A2-cleared medication a patient’s also on. Someone who smokes and is also taking clozapine or olanzapine already has induced CYP1A2 pushing those levels down – adding centanafadine’s own CYP1A2 inhibition on top pulls in the opposite direction on that third drug, which gets genuinely hard to predict without monitoring.

– Alcohol is a genuinely underappreciated one. The extended-release mechanism can get overwhelmed by alcohol – even 5% alcohol accelerates release after about 2 hours, and 20-40% alcohol can dump nearly the whole dose within 90 minutes. Patients should avoid drinking within 2 hours of taking it, not for a vague "be careful" reason but because it can turn an extended-release capsule into something closer to an immediate-release dose.

When you can actually get it

Not yet, is the short answer. Later in 2026 or 2027 most likely.

The FDA approved it July 2026, but the label itself lists the controlled substance schedule as "pending" – it hasn’t gone through DEA scheduling yet, which typically takes up to about three months for a new CNS stimulant.

Otsuka says they expect commercial availability later this year in 2026. Until that scheduling is final, there’s no NDC number active at a pharmacy, no prescribing happening, nothing to send in.

What it’ll probably cost

Nobody knows yet, officially. Otsuka hasn’t announced a price, and there’s no copay card or patient assistance program live as of this writing.

The closest comparison point is Qelbree (viloxazine), the last new branded non-stimulant ADHD medication, which runs somewhere around $360-530/month without insurance, with a manufacturer copay card that can bring it down to a much smaller copay for commercially insured patients (not government-insured ones – that exclusion is standard for these programs). I’d expect Simtriyo to land in a similar range, maybe higher given it’s a new mechanism.

On insurance coverage: I’d bet on needing prior authorization and requiring 1-2 other med trials first (of a stimulant or possibly nonstimulant). Of course, every insurance might have its own unique hoops to jump through. This is similar to requirements for Qelbree.

Many patients with ADHD have already tried 1-2 medicines though, making it a real possibility if your doctor can send in a prior authorization form.

But keep in mind that "covered" and "affordable" aren’t the same thing. Sometimes "covered" means 100%, 80%, you pay a $25-100 co-pay – or, and this happened once – one patient said their insurance "covered something" and they tossed in $20 on a $600 medication. So, sometimes unhelpful.

It’s possible that once it’s commercially available, there will be a manufacturer website, probably Otsuka’s, where there are sometimes programs to help you locate and pay for it if you have a commercial (non-government) insurance plan. Not always though.

Discount pharmacies like Mark Cuban’s CostPlus often don’t dispense controlled substances.

And not all pharmacies accept GoodRx coupons for controlled substances since about 2020. (You have to check with your individual pharmacy).

Where I land on it

I think this is a genuinely interesting new option, mechanistically, for patients who’ve had a rough time with stimulant side effects or with atomoxetine’s slow onset and GI issues.

It’s not going to replace stimulants for most people – the effect sizes are smaller – and it’s not actually the "gentle non-stimulant alternative" that some of the early coverage is implying, because regulators are treating its abuse potential seriously enough to schedule it. But we’ll have to see if it actually feels more gentle – which is what a lot of my patients look for.

Like Qelbree, it’s new and exciting and a possible option for those who have tried 1-2 medicines already and have commercial insurance (or are okay with paying $400-600 monthly for a medicine). However also like Qelbree, it’s protected by patent (brand name only) for over a decade, which affects price and accessibility. I’m often gravitating away from it, since other medicines offer more ease, accessibility, cost-effectiveness, work faster, or meet your goals in some other way. The onset of benefits seems similar to Qelbree: where benefits are felt within a week and reach near max benefit by 1.5 months (vs minimal benefit with Strattera by week 1, with continued slow improvement over up to 6 months). The downside of Simtriyo vs this option though is that on top of those barriers, it’s also controlled.

I’m not going to be able to use it for a while yet, since it isn’t available. But I’ll be paying attention once the DEA scheduling lands, mostly for patients who’ve cycled through the usual options without a great fit.

Frequently asked questions

Is Simtriyo a stimulant or a non-stimulant?

The FDA classifies it as a CNS stimulant, based on human abuse-potential data, even though its mechanism (blocking reuptake rather than forcing dopamine release) more closely resembles non-stimulants like atomoxetine.

Can I take Simtriyo with my SSRI or SNRI?

There’s no absolute contraindication, but the label flags a serotonin syndrome risk with any serotonergic medication, so it needs monitoring. Unlike atomoxetine, there’s no CYP2D6 interaction to worry about – centanafadine is metabolized by monoamine oxidase A instead.

When will Simtriyo be available at pharmacies?

Not yet. It’s FDA-approved but still waiting on DEA controlled-substance scheduling, which Otsuka expects to complete later this year.

How much will Simtriyo cost?

Pricing hasn’t been announced. Qelbree, a comparable recent branded ADHD medication, runs roughly $360-530/month without insurance as a rough reference point.

Is Simtriyo the same as Vyvanse or Adderall?

No. Those are amphetamines that force dopamine release. Centanafadine blocks reuptake of norepinephrine, dopamine, and serotonin without causing release, and its efficacy in trials was more modest than amphetamine-based stimulants.

Can children take Simtriyo?

It’s approved for kids 6 and up weighing at least 20 kg, but it carries a boxed warning for increased suicidal ideation and behavior in the 6-12 age group specifically, which needs close monitoring.